1.
Nature
; 614(7948): 399, 2023 02.
Article
in English
| MEDLINE | ID: covidwho-2327708
2.
Nature
; 2023 May 04.
Article
in English
| MEDLINE | ID: covidwho-2313338
3.
Nature
; 617(7960): 229-230, 2023 May.
Article
in English
| MEDLINE | ID: covidwho-2313337
4.
Nature
; 614(7949): 603, 2023 02.
Article
in English
| MEDLINE | ID: covidwho-2253557
Subject(s)
Clinical Trials as Topic , Disease Outbreaks , Marburg Virus Disease , Marburgvirus , Viral Vaccines , Humans , Disease Outbreaks/prevention & control , Disease Outbreaks/statistics & numerical data , Marburg Virus Disease/epidemiology , Marburg Virus Disease/prevention & control , Marburg Virus Disease/virology , Time Factors
5.
Nature
; 614(7946): 22-25, 2023 02.
Article
in English
| MEDLINE | ID: covidwho-2221784
6.
Nature
; 613(7943): 222-223, 2023 01.
Article
in English
| MEDLINE | ID: covidwho-2185709
Subject(s)
COVID-19 , Internationality , SARS-CoV-2 , Uncertainty , Humans , COVID-19/epidemiology , COVID-19/virology , SARS-CoV-2/classification , United States/epidemiology
7.
Nature
; 613(7942): 13-14, 2023 01.
Article
in English
| MEDLINE | ID: covidwho-2185695
8.
Nature
; 612(7941):614, 2022.
Article
in English
| ProQuest Central | ID: covidwho-2185685
ABSTRACT
Confronted with the prospect of stopping work, Cao realized that the methods he had specialized in could be used to study the antibodies triggered by infection with SARS-CoV-2. Cao - who leads much of the COVID-19 work in Xie's group - started his pandemic efforts by screening people who had recovered from COVID-19 for antibodies that could be used in treatment. Working with a Chinese drug company, the group picked two of the most potent infection-blocking, or neutralizing, antibodies and began trialling them in people with COVID-19.
9.
Nature
; 611(7935): 213-214, 2022 11.
Article
in English
| MEDLINE | ID: covidwho-2096652
10.
Nature
; 610(7931): 239-241, 2022 10.
Article
in English
| MEDLINE | ID: covidwho-2050306
11.
Nature
; 609(7929): 883-885, 2022 09.
Article
in English
| MEDLINE | ID: covidwho-2050296
12.
Nature
; 609(7928): 661-662, 2022 09.
Article
in English
| MEDLINE | ID: covidwho-2050295
Subject(s)
Artificial Intelligence , Proteins , Research Personnel , Drug Design/trends , Synthetic Biology/trends
13.
Nature
; 2022 Aug 11.
Article
in English
| MEDLINE | ID: covidwho-1991541
14.
Nature
; 608(7923): 462-463, 2022 08.
Article
in English
| MEDLINE | ID: covidwho-1984375
15.
Nature
; 607(7917): 18-19, 2022 07.
Article
in English
| MEDLINE | ID: covidwho-1908136
Subject(s)
COVID-19 Vaccines , COVID-19 , SARS-CoV-2 , COVID-19/immunology , COVID-19/prevention & control , COVID-19/virology , COVID-19 Vaccines/genetics , COVID-19 Vaccines/immunology , COVID-19 Vaccines/supply & distribution , Humans , SARS-CoV-2/classification , SARS-CoV-2/genetics , SARS-CoV-2/immunology
16.
Nature
; 606(7914): 452-455, 2022 06.
Article
in English
| MEDLINE | ID: covidwho-1890140
Subject(s)
COVID-19 , SARS-CoV-2 , COVID-19/virology , Humans , SARS-CoV-2/classification , SARS-CoV-2/genetics , Time Factors
17.
Nature
; 605(7909): 204-206, 2022 05.
Article
in English
| MEDLINE | ID: covidwho-1830022
Subject(s)
COVID-19 , SARS-CoV-2 , COVID-19/epidemiology , Disease Outbreaks , Forecasting , Humans , Mutation , SARS-CoV-2/genetics
18.
Nature
; 2022 Mar 30.
Article
in English
| MEDLINE | ID: covidwho-1768798
19.
Nature
; 587(7834): 337-338, 2020 11.
Article
in English
| MEDLINE | ID: covidwho-1671518
Subject(s)
Coronavirus Infections/immunology , Coronavirus Infections/prevention & control , Pandemics/prevention & control , Pneumonia, Viral/immunology , Pneumonia, Viral/prevention & control , Vaccination/standards , Viral Vaccines/immunology , Adult , Age Factors , Aged , Aging/immunology , Biotechnology/trends , COVID-19 , COVID-19 Vaccines , Clinical Trials, Phase III as Topic , Coronavirus Infections/genetics , Humans , Time Factors , Viral Vaccines/adverse effects , Viral Vaccines/genetics
20.
Nature
; 2022 Feb 03.
Article
in English
| MEDLINE | ID: covidwho-1671530